Trial Profile
Phase II Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2022
Price :
$35
*
At a glance
- Drugs Vismodegib (Primary)
- Indications Basal cell cancer
- Focus Therapeutic Use
- Acronyms VISMONEO
- 14 Oct 2022 Status changed from active, no longer recruiting to completed.
- 26 Aug 2020 Planned End Date changed from 1 Dec 2020 to 1 May 2021.
- 26 Aug 2020 Planned primary completion date changed from 1 Dec 2019 to 1 May 2021.